Sequenta has introduced a sequencing-based test for minimal residual disease (MRD) for leukemia and lymphoma. The ClonoSIGHT test utilizes the company's proprietary LymphoSIGHT technology, which works by sequencing DNA signatures that are ...
Tags: Sequenta, sequencing-based test, minimal residual disease